Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A. Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale. The week marked an extension … Read more